Citation Impact
Citing Papers
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
Microbiota in health and diseases
2022 Standout
Gastric cancer
2016 Standout
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
2007
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins
2014
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
1998
Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II
2010
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
2011 Standout
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles
2004
Effects of the Antifungal Agents on Oxidative Drug Metabolism
2000
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
1997
Treatment of Multidrug-Resistant Acinetobacter baumannii Meningitis with Ampicillin/Sulbactam
1997
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
1996
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
2002
Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition
2000
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Nontraditional Dosing of Ampicillin‐Sulbactam for Multidrug‐Resistant Acinetobacter baumannii Meningitis
2002
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers
1995
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
UREIDOPENICILLINS AND BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS
2000
Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects
2005
Tacrolimus
1993
Clinical application of oxaliplatin in epithelial ovarian cancer
2006
Anti-proliferative activity and mechanism of action of titanocene dichloride
1998
Cisplatin Nephrotoxicity: A Review
2007 Standout
Management of meningitis due to antibiotic-resistant Acinetobacter species
2009
New Cisplatin Analogues in Development
1993
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
2016
Molecular mechanisms of cisplatin resistance
2011 Standout
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer
1992
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
1999 Standout
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Pharmacokinetics of Antimycobacterial Drugs in Patients with Tuberculosis, AIDS, and Diarrhea
1997
Gout
2016 Standout
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
2004 Standout
Clinical Pharmacokinetics of Tacrolimus
1995 Standout
Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in Colon Cancer Cells
2005
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
2008 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
1996
The effect of chronic renal failure on drug metabolism and transport
2008
Tumour-inhibiting platinum complexes—state of the art and future perspectives
2003
Oxaliplatin clinical activity: a review
2000
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Ongoing and unsaid on oxaliplatin: the hope
1998
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Herb-Drug Interactions
2005 Standout
Treatment of early AIDS-related Kaposiʼs sarcoma with oral all-trans-retinoic acid
1998
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity
2007
Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA
1998
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
1993
New platinum antitumor complexes
1993
Kaposi's Sarcoma
2000 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Acinetobacter baumannii : Emergence of a Successful Pathogen
2008 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
2011 Standout
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Organometallic Anticancer Compounds
2010 Standout
Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults
2005 Standout
Nanoencapsulation, Nano-guard for Pesticides: A New Window for Safe Application
2016 Standout
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
2000
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Current status of trans-platinum compounds in cancer therapy
2001
Additions to Metal-Activated Organonitriles
2002 Standout
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Cellular and molecular pharmacology of oxaliplatin.
2002
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
2009 Standout
Genome-Wide Identification of Genes Conferring Resistance to the Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C
2004
Use of clays as drug delivery systems: Possibilities and limitations
2006 Standout
Pharmacokinetics of Sulbactam/Ampicillin in Humans: A Review
1986
Cellular and molecular aspects of drugs of the future: oxaliplatin
2002
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis
1987
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
2000
Three Decades of β-Lactamase Inhibitors
2010 Standout
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
2010 Standout
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Sulbactam/Ampicillin
1987
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
2000
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Works of G Fredj being referenced
RELATIONSHIP BETWEEN GRAFT CYTOCHROME P-450 3A CONTENT AND EARLY MORBIDITY AFTER LIVER TRANSPLANTATION1
1993
Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients
1997
Treatment of AIDS-associated Kaposi’s sarcoma with oral tretinoin
1994
Changes in erythromycin pharmacokinetics induced by renal failure.
1987
Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone
1986
[Topical digestive drugs with a clay base. Influence on the absorption of cimetidine].
1986
Rapid determination of pyrazinamide in biological fluids by high-performance liquid chromatography
1985
Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation.
1991
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
1989
FK 506/fluconazole interaction enhances FK 506 nephrotoxicity.
1994
Penetration of Sulbactam into the Cerebrospinal Fluid of Patients with Bacterial Meningitis Receiving Ampicillin Therapy
1986